The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease
Transl Vis Sci Technol
.
2021 Jul 1;10(8):4.
doi: 10.1167/tvst.10.8.4.
Authors
Marco H Ji
1
,
Alexander Kreymerman
1
2
,
Kinsley Belle
1
,
Benjamin K Ghiam
3
,
Stephanie R Muscat
1
,
Vinit B Mahajan
1
,
Gregory M Enns
4
,
Mark Mercola
2
,
Edward H Wood
1
2
Affiliations
1
Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
2
Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
3
Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA.
4
Department of Pediatrics, Division of Medical Genetics, Stanford University School of Medicine, Palo Alto, CA, USA.
PMID:
34232272
PMCID:
PMC8267180
DOI:
10.1167/tvst.10.8.4
Abstract
Mitochondria are viable therapeutic targets for a broad spectrum of ocular diseases.
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Eye Diseases* / drug therapy
Humans
Mitochondria*
Grant support
P30 EY026877/EY/NEI NIH HHS/United States